Merkel Cell Carcinoma of Skin clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Safety Study of KUP-101A in Advanced Solid Tumors

This is an early-stage study testing a new drug called KUP-101A in patients with advanced solid cancers (like lung, colon, or breast cancer) that haven't responded to standard treatments. The drug works by activating the immune system to fight cancer.

Lab test for a new Merkel cell cancer treatment

This trial is testing a lab method to see if a specific type of immunotherapy can work against Merkel cell carcinoma. It may help find new treatment options for people with this skin cancer.

Studying insurance for skin cancer treatment

This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.

Testing NEO212 for brain tumors and metastases

This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.

National registry for rare skin cancer diagnoses

This trial is a French national database that collects information from people with certain rare skin cancers. It may help researchers better understand these cancers and improve future care, using real-world patient data.

Cemiplimab before surgery for Merkel cell and skin cancers

This early-phase study tests cemiplimab (an immune therapy that helps your immune system attack cancer) given before surgery. It aims to shrink tumors and improve outcomes for people with Merkel cell cancer or certain locally advanced skin squamous cell cancers (CSCC).

Beta-only IL-2 therapy for advanced solid tumors

This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.

Pembrolizumab before surgery for resectable Merkel cell cancer

This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.

Trial tests targeted radiation plus immunotherapy after anti–PD-1 failure

This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.

Immunotherapy with prednisone and sirolimus for transplant skin cancer

This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.

Nicotinamide to prevent skin cancer after organ transplant

This trial tests nicotinamide (a vitamin-like medicine) to help prevent new keratinocyte skin cancers in people who have had a kidney, liver, heart, or lung transplant. It may lower the chance of developing new skin tumors while you continue your usual transplant anti-rejection medicines.

Home cancer treatment vs clinic treatment for advanced cancer

This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.

EMLA cream for pain during lymphoscintigraphy for skin cancer

This trial tests whether EMLA cream can reduce pain from injections needed to map lymph nodes for certain skin cancers. If you are scheduled for lymphoscintigraphy and sentinel lymph node biopsy, you may be eligible.

Study of VET3-TGI for advanced solid tumors

This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.

Electrochemotherapy for internal organ tumors

This trial tests a treatment called electrochemotherapy for tumors in internal organs (like the liver or pancreas) when standard treatments are no longer possible. It uses a drug called bleomycin plus electric pulses to target cancer cells.

IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma

This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.

Vaccine plus immunotherapy for Merkel cell cancer

This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.

Study of a new drug for small cell lung cancer and neuroendocrine tumors

This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.

Study of AZD6750 for advanced solid tumors

This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.

TIL Therapy for Advanced Skin Cancer Patients

This study tests a personalized cell therapy called TIL (tumor-infiltrating lymphocytes) for people with advanced skin cancers that have not responded to immunotherapy. Doctors take your tumor cells, grow immune cells from them, and then infuse them back to fight the cancer.

Share skin samples for dermatology research

This study collects and stores biological samples (biospecimens) from people with skin conditions, people at risk, or healthy volunteers. It helps researchers better understand dermatologic diseases and support future skin research.

Pembrolizumab before surgery or radiation for high-risk skin SCC

This Phase 2 trial tests pembrolizumab (an immune therapy) given before surgery to see if it can help control high-risk invasive cutaneous squamous cell carcinoma. The goal is to improve outcomes by treating cancer earlier and then following with standard surgery and radiation if needed.

Study of IDE849 for DLL3-positive cancers like SCLC

This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.